Emerging medical therapies in crush syndrome – progress report from basic sciences and potential future avenues

References

• Better OS. History of the crush syndrome: from the earthquakes of Messina, Sicily 1909 to Spitak, Armenia 1988. Am J Nephrol. 1997;17(3–4):392–394.
   PubMed Web of Science ®Google Scholar
• Bywaters EG, Beall D. Crush injuries with impairment of renal function. Br Med J. 1941;1(4185):427–432.
   PubMedGoogle Scholar
• Bywaters EG, Beall D. Crush injuries with impairment of renal function. 1941. J Am Soc Nephrol. 1998;9(2):322–332.
   PubMedGoogle Scholar
• Oda J, Tanaka H, Yoshioka T, et al. Analysis of 372 patients with Crush syndrome caused by the Hanshin-Awaji earthquake. J Trauma. 1997;42(3):470–475. discussion 475–476.
   PubMedGoogle Scholar
• Better OS. The crush syndrome revisited (1940–1990). Nephron. 1990;55(2):97–103.
   PubMed Web of Science ®Google Scholar
• Hertzberg D, Ryden L, Pickering JW, et al. Acute kidney injury-an overview of diagnostic methods and clinical management. Clin Kidney J. 2017;10(3):323–331.
   PubMed Web of Science ®Google Scholar
• Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury. Compr Physiol. 2012;2(2):1303–1353.
   PubMed Web of Science ®Google Scholar
• Odeh M. The role of reperfusion-induced injury in the pathogenesis of the crush syndrome. N Engl J Med. 1991;324(20):1417–1422.
   PubMed Web of Science ®Google Scholar
• Gonzalez D. Crush syndrome. Crit Care Med. 2005;33(1 Suppl):S34–S41.
   PubMedGoogle Scholar
• Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62–72.
   PubMed Web of Science ®Google Scholar
• Song XB, Zhou XL, Ni SZ, et al. Early fluid resuscitation with hypertonic solution in a rat crush injury model. Shock. 2013;39(5):453–459.
   PubMed Web of Science ®Google Scholar
• Sever MS, Vanholder R, Lameire N. Management of crush-related injuries after disasters. N Engl J Med. 2006;354(10):1052–1063.
   PubMed Web of Science ®Google Scholar
• AlEnezi F, Alhazzani W, Ma J, et al. Continuous venovenous hemofiltration versus continuous venovenous hemodiafiltration in critically ill patients: a retrospective cohort study from a Canadian tertiary centre. Can Respir J. 2014;21(3):176–180.
   PubMed Web of Science ®Google Scholar
• Cuong NT, Abe C, Binh NH, et al. Sivelestat improves outcome of crush injury by inhibiting high-mobility group box 1 in rats. Shock. 2013;39(1):89–95.
   PubMed Web of Science ®Google Scholar
• Shimazaki J, Matsumoto N, Ogura H, et al. Systemic involvement of high-mobility group box 1 protein and therapeutic effect of anti-high-mobility group box 1 protein antibody in a rat model of crush injury. Shock. 2012;37(6):634–638.
   PubMed Web of Science ®Google Scholar
• Sever MS, Vanholder R. Management of crush victims in mass disasters: highlights from recently published recommendations. Clin J Am Soc Nephrol. 2013;8(2):328–335.
   PubMed Web of Science ®Google Scholar
• Koyner JL, Sher Ali R, Murray PT. Antioxidants. Do they have a place in the prevention or therapy of acute kidney injury? Nephron Exp Nephrol. 2008;109(4):e109–e117.
   PubMedGoogle Scholar
• Plotnikov EY, Chupyrkina AA, Jankauskas SS, et al. Mechanisms of nephroprotective effect of mitochondria-targeted antioxidants under rhabdomyolysis and ischemia/reperfusion. Biochim Biophys Acta. 2011;1812(1):77–86.
   PubMed Web of Science ®Google Scholar
• Plotnikov EY, Silachev DN, Chupyrkina AA, et al. New-generation Skulachev ions exhibiting nephroprotective and neuroprotective properties. Biochemistry Mosc. 2010;75(2):145–150.
   PubMed Web of Science ®Google Scholar
• Anderson R, Franch A, Castell M, et al. Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Res Ther. 2010;12(4):R147.
   PubMed Web of Science ®Google Scholar
• Ebata T, Hayasaka H. Effects of aldosterone and dexamethasone on blood chemical mediators in endotoxin shock. Jpn J Surg. 1979;9(1):79–85.
   PubMedGoogle Scholar
• Ebata T, Osanai H, Kobayashi K, et al. Effect of dexamethasone in endotoxin shock–difference in anti-toxic potency among ester types of dexamethasone (author’s transl). Masui. The Japanese J Anesthesiol. 1978;27(4):355–359.
   PubMedGoogle Scholar
• Tang HX, Fan XM. Effect of dexamethasone, aminoguanidin, amrinone on oxygen utilization in endotoxin shock rabbits. Zhonghua er ke za zhi = Chinese journal of pediatrics. 2003;41(4):282–285.
   PubMedGoogle Scholar
• Murata I, Goto M, Komiya M, et al. Early therapeutic intervention for crush syndrome: characterization of intramuscular administration of dexamethasone by pharmacokinetic and biochemical parameters in rats. Biol Pharm Bull. 2016;39(9):1424–1431.
   PubMed Web of Science ®Google Scholar
• Murata I, Otsuka A, Hara C, et al. Pharmacokinetics characteristics of dexamethasone in Crush syndrome model rats. Yakugaku Zasshi. 2015;135(2):315–322.
   PubMed Web of Science ®Google Scholar
• Murata I, Ooi K, Shoji S, et al. Acute lethal crush-injured rats can be successfully rescued by a single injection of high-dose dexamethasone through a pathway involving PI3K-Akt-eNOS signaling. J Trauma Acute Care Surg. 2013;75(2):241–249.
   PubMed Web of Science ®Google Scholar
• Adamson R, Rambaran C, D’Cruz DP. Anabolic steroid-induced rhabdomyolysis. Hosp Med. 2005;66(6):362.
   PubMedGoogle Scholar
• Daniels JM, van Westerloo DJ, de Hon OM, et al. [Rhabdomyolysis in a bodybuilder using steroids]. Ned Tijdschr Geneeskd. 2006;150(19):1077–1080.
   PubMedGoogle Scholar
• Schouten VL, van der Spoel JI. Massive rhabdomyolysis due to corticosteroids and muscle blocking agents, proven by rechallenge. Neth J Crit Care. 2019;27(6):246–248.
   Google Scholar
• Chung HY, Baek BS, Song SH, et al. Xanthine dehydrogenase/xanthine oxidase and oxidative stress. Age (Omaha). 1997;20(3):127–140.
   PubMedGoogle Scholar
• Touyz RM. Chapter 69 - reactive oxygen species and oxidative stress. In: Robertson D, Biaggioni I, Burnstock G, Low PA, Paton JFR, editors. Primer on the autonomic nervous system. 3rd ed. San Diego: Academic Press; 2012. p. 335–338.
   Google Scholar
• George J, Struthers AD. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag. 2009;5(1):265–272.
   PubMedGoogle Scholar
• Ibrahim B, Stoward PJ. The histochemical localization of xanthine oxidase. Histochem J. 1978;10(5):615–617.
   PubMedGoogle Scholar
• Cighetti G, Del Puppo M, Paroni R, et al. Lack of conversion of xanthine dehydrogenase to xanthine oxidase during warm renal ischemia. FEBS Lett. 1990;274(1–2):82–84.
   PubMed Web of Science ®Google Scholar
• Saksela M, Lapatto R, Raivio KO. Irreversible conversion of xanthine dehydrogenase into xanthine oxidase by a mitochondrial protease. FEBS Lett. 1999;443(2):117–120.
   PubMed Web of Science ®Google Scholar
• Glantzounis GK, Tsimoyiannis EC, Kappas AM, et al. Uric acid and oxidative stress. Curr Pharm Des. 2005;11(32):4145–4151.
   PubMed Web of Science ®Google Scholar
• Hellsten Y, Ahlborg G, Jensen-Urstad M, et al. Indication of in vivo xanthine oxidase activity in human skeletal muscle during exercise. Acta Physiol Scand. 1988;134(1):159–160.
   PubMedGoogle Scholar
• Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87–114.
   PubMed Web of Science ®Google Scholar
• White WB. Gout, xanthine oxidase inhibition, and cardiovascular outcomes. Circulation. 2018;138(11):1127–1129.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SS, Jung MH, et al. N-acetylcysteine attenuates glycerol-induced acute kidney injury by regulating MAPKs and Bcl-2 family proteins. Nephrol Dial Transplant. 2010;25(5):1435–1443.
   PubMed Web of Science ®Google Scholar
• Homsi E, de Brito SM, Janino P. Silymarin exacerbates p53-mediated tubular apoptosis in glycerol-induced acute kidney injury in rats. Ren Fail. 2010;32(5):623–632.
   PubMed Web of Science ®Google Scholar
• Gois PHF, Canale D, Volpini RA, et al. Allopurinol attenuates rhabdomyolysis-associated acute kidney injury: renal and muscular protection. Free Radic Biol Med. 2016;101:176–189.
   PubMed Web of Science ®Google Scholar
• Bryan NS, Fernandez BO, Bauer SM, et al. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat Chem Biol. 2005;1(5):290–297.
   PubMed Web of Science ®Google Scholar
• Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol. 2001;11(2):66–75.
   PubMed Web of Science ®Google Scholar
• Raat NJ, Noguchi AC, Liu VB, et al. Dietary nitrate and nitrite modulate blood and organ nitrite and the cellular ischemic stress response. Free Radic Biol Med. 2009;47(5):510–517.
   PubMed Web of Science ®Google Scholar
• Cui H, Feng Y, Shu C, et al. Dietary nitrate protects against skin flap ischemia-reperfusion injury in rats via modulation of antioxidative action and reduction of inflammatory responses. Front Pharmacol. 2019;10:1605.
   PubMed Web of Science ®Google Scholar
• Murata I, Nozaki R, Ooi K, et al. Nitrite reduces ischemia/reperfusion-induced muscle damage and improves survival rates in rat crush injury model. J Trauma Acute Care Surg. 2012;72(6):1548–1554.
   PubMed Web of Science ®Google Scholar
• Murata I, Miyake Y, Takahashi N, et al. Low-dose sodium nitrite fluid resuscitation prevents lethality from crush syndrome by improving nitric oxide consumption and preventing myoglobin cytotoxicity in kidney in a rat model. Shock. 2017;48(1):112–118.
   PubMed Web of Science ®Google Scholar
• Kobayashi J, Murata I. Nitrite as a pharmacological intervention for the successful treatment of crush syndrome. Physiol Rep. 2018;6(5):e13633.
   Web of Science ®Google Scholar
• Zhao CL, Ron S, Liu CG, et al. Blocking effect of anisodamine on acetylcholine receptor channels. Zhongguo Yao Li Xue Bao. 1993;14(2):190–192.
   PubMed Web of Science ®Google Scholar
• Poupko J, Baskin S, Moore E. The pharmacological properties of anisodamine. J Appl Toxicol. 2007;27(2):116–121.
   PubMed Web of Science ®Google Scholar
• Zhao T, Li DJ, Liu C, et al. Beneficial effects of anisodamine in shock involved cholinergic anti-inflammatory pathway. Front Pharmacol. 2011;2:23.
   PubMed Web of Science ®Google Scholar
• Eisenkraft A, Falk A. Possible role for anisodamine in organophosphate poisoning. Br J Pharmacol. 2016;173(11):1719–1727.
   PubMed Web of Science ®Google Scholar
• Yu JG, Fan BS, Guo JM, et al. Anisodamine ameliorates hyperkalemia during crush syndrome through estradiol-induced enhancement of insulin sensitivity. Front Pharmacol. 2019;10:1444.
   PubMed Web of Science ®Google Scholar
• Fan BS, Zhang EH, Wu M, et al. Activation of α7 nicotinic acetylcholine receptor decreases on-site mortality in crush syndrome through insulin signaling-Na/K-ATPase pathway. Front Pharmacol. 2016;7:79.
   PubMed Web of Science ®Google Scholar
• Li YF, Xu BY, An R, et al. Protective effect of anisodamine in rats with glycerol-induced acute kidney injury. BMC Nephrol. 2019;20(1):223.
   PubMedGoogle Scholar
• Sinclair S. Chinese herbs: a clinical review of Astragalus, Ligusticum, and Schizandrae. Altern Med Rev. 1998;3(5):338–344.
   PubMedGoogle Scholar
• Graziani V, Scognamiglio M, Esposito A, et al. Chemical diversity and biological activities of the saponins isolated from Astragalus genus: focus on Astragaloside IV. Phytochem Rev. 2019;18(4):1133–1166.
   Web of Science ®Google Scholar
• Chen XJ, Meng D, Feng L, et al. Protective effect of astragalosides on myocardial injury by isoproterenol in SD rats. Am J Chin Med. 2006;34(6):1015–1025.
   PubMed Web of Science ®Google Scholar
• Li ZP, Cao Q. Effects of astragaloside IV on myocardial calcium transport and cardiac function in ischemic rats. Acta Pharmacol Sin. 2002;23(10):898–904.
   PubMed Web of Science ®Google Scholar
• Qu YZ, Li M, Zhao YL, et al. Astragaloside IV attenuates cerebral ischemia-reperfusion-induced increase in permeability of the blood-brain barrier in rats. Eur J Pharmacol. 2009;606(1–3):137–141.
   PubMed Web of Science ®Google Scholar
• Zhang WD, Chen H, Zhang C, Liu RH, Li HL, et al. Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro. Planta Med. 2006;72(1):4–8.
   PubMed Web of Science ®Google Scholar
• Tan S, Wang G, Guo Y, et al. Preventive effects of a natural anti-inflammatory agent, astragaloside IV, on ischemic acute kidney injury in rats. Evid Based Complement Alternat Med. 2013;2013:284025.
   PubMed Web of Science ®Google Scholar
• Qi W, Niu J, Qin Q, et al. Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells. Cell Stress Chaperones. 2014;19(1):105–114.
   PubMed Web of Science ®Google Scholar
• Xu C, Tang F, Lu M, et al. Astragaloside IV improves the isoproterenol-induced vascular dysfunction via attenuating eNOS uncoupling-mediated oxidative stress and inhibiting ROS-NF-κB pathways. Int Immunopharmacol. 2016;33:119–127.
   PubMed Web of Science ®Google Scholar
• Xu C, Tang F, Lu M, et al. Pretreatment with Astragaloside IV protects human umbilical vein endothelial cells from hydrogen peroxide induced oxidative stress and cell dysfunction via inhibiting eNOS uncoupling and NADPH oxidase - ROS - NF-κB pathway. Can J Physiol Pharmacol. 2016;94(11):1132–1140.
   PubMed Web of Science ®Google Scholar
• Murata I, Abe Y, Yaginuma Y, et al. Astragaloside-IV prevents acute kidney injury and inflammation by normalizing muscular mitochondrial function associated with a nitric oxide protective mechanism in crush syndrome rats. Ann Intensive Care. 2017;7(1):90.
   PubMedGoogle Scholar
• Han Y, Shang Q, Yao J, et al. Hydrogen sulfide: a gaseous signaling molecule modulates tissue homeostasis: implications in ophthalmic diseases. Cell Death Dis. 2019;10(4):293.
   PubMedGoogle Scholar
• Zoccali C, Catalano C, Rastelli S. Blood pressure control: hydrogen sulfide, a new gasotransmitter, takes stage. Nephrol Dial Transplant. 2009;24(5):1394–1396.
   PubMed Web of Science ®Google Scholar
• Yang G, Wang R. H2S and blood vessels: an overview. Handb Exp Pharmacol. 2015;230:85–110.
   PubMedGoogle Scholar
• Kimura H. The physiological role of hydrogen sulfide and beyond. Nitric Oxide. 2014;41:4–10.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Goto Y, Kimura H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid Redox Signal. 2010;12(1):1–13.
   PubMed Web of Science ®Google Scholar
• Teksen Y, Kadioglu E, Kocak C, et al. Effect of hydrogen sulfide on kidney injury in rat model of crush syndrome. J Surg Res. 2019;235:470–478.
   PubMed Web of Science ®Google Scholar
• Ahmad R, Raina D, Meyer C, et al. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem. 2006;281(47):35764–35769.
   PubMed Web of Science ®Google Scholar
• Nagasu H, Sogawa Y, Kidokoro K, et al. Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function. Faseb J. 2019;33(11):12253–12263.
   PubMed Web of Science ®Google Scholar
• Kadioglu E, Teksen Y, Kocak C, et al. Beneficial effects of bardoxolone methyl, an Nrf2 activator, on crush-related acute kidney injury in rats. Eur J Trauma Emerg Surg. 2019.DOI: https://doi.org/10.1007/s00068-019-01216-z
   Google Scholar
• Vaziri ND, Liu S, Farzaneh SH, et al. Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney disease. Free Radic Biol Med. 2015;86:374–381.
   PubMed Web of Science ®Google Scholar
• Perveen K, Hanif F, Jawed H, et al. N-(2-hydroxy phenyl) acetamide: a novel suppressor of Toll-like receptors (TLR-2 and TLR-4) in adjuvant-induced arthritic rats. Mol Cell Biochem. 2014;394(1–2):67–75.
   PubMed Web of Science ®Google Scholar
• Jawed H, Shah SU, Jamall S, et al. N-(2-hydroxy phenyl) acetamide inhibits inflammation-related cytokines and ROS in adjuvant-induced arthritic (AIA) rats. Int Immunopharmacol. 2010;10(8):900–905.
   PubMed Web of Science ®Google Scholar
• Perveen K, Hanif F, Jawed H, et al. Protective efficacy of N-(2-hydroxyphenyl) acetamide against adjuvant-induced arthritis in rats. BioMed Res Int. 2013;2013:1–8.
   Web of Science ®Google Scholar
• Siddiqui RA, Simjee SU, Kabir N, et al. N-(2-hydroxyphenyl)acetamide and its gold nanoparticle conjugation prevent glycerol-induced acute kidney injury by attenuating inflammation and oxidative injury in mice. Mol Cell Biochem. 2019;450(1–2):43–52.
   PubMed Web of Science ®Google Scholar
• Ito K, Mizutani A, Kira S, et al. Effect of Ulinastatin, a human urinary trypsin inhibitor, on the oleic acid-induced acute lung injury in rats via the inhibition of activated leukocytes. Injury. 2005;36(3):387–394.
   PubMed Web of Science ®Google Scholar
• Umeadi C, Kandeel F, Al-Abdullah I. Ulinastatin is a novel protease inhibitor and neutral protease activator. Transplant Proc. 2008;40(2):387–389.
   PubMed Web of Science ®Google Scholar
• Atal S, Atal S. Ulinastatin – a newer potential therapeutic option for multiple organ dysfunction syndrome. J Basic Clin Physiol Pharmacol. 2016;27(2):91–99.
   PubMedGoogle Scholar
• Yang XY, Song J, Hou SK, et al. Ulinastatin ameliorates acute kidney injury induced by crush syndrome inflammation by modulating Th17/Treg cells. Int Immunopharmacol. 2020;81:106265.
   PubMed Web of Science ®Google Scholar
• Sasaki R. Pleiotropic functions of erythropoietin. Intern Med. 2003;42(2):142–149.
   PubMed Web of Science ®Google Scholar
• Zhang G, Lehmann HC, Bogdanova N, et al. Erythropoietin enhances nerve repair in anti-ganglioside antibody-mediated models of immune neuropathy. PloS One. 2011;6(10):e27067.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin. Biochim Biophys Acta. 2007;1776(1):1–9.
   PubMed Web of Science ®Google Scholar
• Sharples EJ, Thiemermann C, Yaqoob MM. Mechanisms of disease: cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat Clin Pract Nephrol. 2005;1(2):87–97.
   PubMedGoogle Scholar
• Arcasoy MO. Non-erythroid effects of erythropoietin. Haematologica. 2010;95(11):1803–1805.
   PubMed Web of Science ®Google Scholar
• Yang FL, Subeq YM, Chiu YH, et al. Recombinant human erythropoietin reduces rhabdomyolysis-induced acute renal failure in rats. Injury. 2012;43(3):367–373.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang C, Li J, et al. Erythropoietin protects against rhabdomyolysis-induced acute kidney injury by modulating macrophage polarization. Cell Death Dis. 2017;8(4):e2725.
   PubMedGoogle Scholar
• Zhou J, Bai Y, Jiang Y, et al. Immunomodulatory role of recombinant human erythropoietin in acute kidney injury induced by crush syndrome via inhibition of the TLR4/NF-kappaB signaling pathway in macrophages. Immunopharmacol Immunotoxicol. 2020;42(1):37–47.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee DW, Jung MH, et al. Macrophage depletion ameliorates glycerol-induced acute kidney injury in mice. Nephron Exp Nephrol. 2014;128(1–2):21–29.
   PubMedGoogle Scholar
• Belliere J, Casemayou A, Ducasse L, et al. Specific macrophage subtypes influence the progression of rhabdomyolysis-induced kidney injury. J Am Soc Nephrol. 2015;26(6):1363–1377.
   PubMed Web of Science ®Google Scholar
• Rubio-Navarro A, Carril M, Padro D, et al. CD163-macrophages are involved in rhabdomyolysis-induced kidney injury and may be detected by MRI with targeted gold-coated iron oxide nanoparticles. Theranostics. 2016;6(6):896–914.
   PubMed Web of Science ®Google Scholar
• Okubo K, Kurosawa M, Kamiya M, et al. Macrophage extracellular trap formation promoted by platelet activation is a key mediator of rhabdomyolysis-induced acute kidney injury. Nat Med. 2018;24(2):232–238.
   PubMed Web of Science ®Google Scholar
• Andersson U, Yang H, Harris H. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Semin Immunol. 2018;38:40–48.
   PubMed Web of Science ®Google Scholar
• VanPatten S, Al-Abed Y. High Mobility Group Box-1 (HMGb1): current wisdom and advancement as a potential drug target. J Med Chem. 2018;61(12):5093–5107.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Ono T, Ito T, et al. Hemoperfusion with a high-mobility group box 1 adsorption column can prevent the occurrence of hepatic ischemia-reperfusion injury in rats. Crit Care Med. 2010;38(3):879–885.
   PubMed Web of Science ®Google Scholar
• Kang R, Zhang Q, Hou W, et al. Intracellular Hmgb1 inhibits inflammatory nucleosome release and limits acute pancreatitis in mice. Gastroenterology. 2014;146(4):1097–1107.
   PubMed Web of Science ®Google Scholar
• Luan ZG, Zhang H, Yang PT, et al. HMGB1 activates nuclear factor-κB signaling by RAGE and increases the production of TNF-α in human umbilical vein endothelial cells. Immunobiology. 2010;215(12):956–962.
   PubMed Web of Science ®Google Scholar
• Wu X, Mi Y, Yang H, et al. The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway. Mol Cell Biochem. 2013;380(1–2):249–257.
   PubMed Web of Science ®Google Scholar
• Zhang BF, Wang PF, Cong YX, et al. Anti-high mobility group box-1 (HMGB1) antibody attenuates kidney damage following experimental crush injury and the possible role of the tumor necrosis factor-α and c-Jun N-terminal kinase pathway. J Orthop Surg Res. 2017;12(1):110.
   PubMedGoogle Scholar
• Creagh-Brown BC, Quinlan GJ, Evans TW, et al. The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: an important therapeutic target? Intensive Care Med. 2010;36(10):1644–1656.
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Matsumoto N, Shimazaki J, et al. Therapeutic effectiveness of anti-RAGE antibody administration in a rat model of crush injury. Sci Rep. 2017;7(1):12255.
   PubMedGoogle Scholar
• Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 2015;35(2):e00191.
   PubMed Web of Science ®Google Scholar
• Mishra PJ, Banerjee D. Activation and differentiation of mesenchymal stem cells. Methods Mol Biol. 2017;1554:201–209.
   PubMedGoogle Scholar
• Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317.
   PubMed Web of Science ®Google Scholar
• de Almeida DC, Donizetti-Oliveira C, Barbosa-Costa P, et al. In search of mechanisms associated with mesenchymal stem cell-based therapies for acute kidney injury. Clin Biochem Rev. 2013;34(3):131–144.
   PubMedGoogle Scholar
• Duffy MM, Griffin MD. Back from the brink: a mesenchymal stem cell infusion rescues kidney function in acute experimental rhabdomyolysis. Stem Cell Res Ther. 2014;5(5):109.
   PubMedGoogle Scholar
• Geng Y, Zhang L, Fu B, et al. Mesenchymal stem cells ameliorate rhabdomyolysis-induced acute kidney injury via the activation of M2 macrophages. Stem Cell Res Ther. 2014;5(3):80.
   PubMedGoogle Scholar
• Ogaki S, Taguchi K, Watanabe H, et al. Carbon monoxide-bound red blood cell resuscitation ameliorates hepatic injury induced by massive hemorrhage and red blood cell resuscitation via hepatic cytochrome P450 protection in hemorrhagic shock rats. J Pharm Sci. 2014;103(7):2199–2206.
   PubMed Web of Science ®Google Scholar
• Taguchi K, Ogaki S, Nagasaki T, et al. Carbon monoxide rescues the developmental lethality of experimental rat models of rhabdomyolysis-induced acute kidney injury. J Pharmacol Exp Ther. 2020;372(3):355–365.
   PubMed Web of Science ®Google Scholar
• Murata I, Imanari M, Komiya M, et al. Icing treatment in rats with crush syndrome can improve survival through reduction of potassium concentration and mitochondrial function disorder effect. Exp Ther Med. 2019;19(1):777–785.
   PubMed Web of Science ®Google Scholar